News articles about Clearside Biomedical (NASDAQ:CLSD) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clearside Biomedical earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7904885677138 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of research analysts have recently commented on CLSD shares. Wedbush reissued a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, February 7th. Needham & Company LLC raised their target price on Clearside Biomedical from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, March 6th. BidaskClub raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, December 8th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $25.00 target price on shares of Clearside Biomedical in a research note on Monday, March 5th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $19.83.
Shares of NASDAQ:CLSD traded down $0.38 during midday trading on Thursday, reaching $10.31. The company had a trading volume of 234,367 shares, compared to its average volume of 872,526. The company has a quick ratio of 2.90, a current ratio of 2.90 and a debt-to-equity ratio of 0.22. Clearside Biomedical has a 1-year low of $5.30 and a 1-year high of $15.06. The firm has a market capitalization of $331.26, a price-to-earnings ratio of -4.42 and a beta of -7.02.
In related news, Director Gerald D. Cagle purchased 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 22nd. The stock was acquired at an average price of $11.89 per share, for a total transaction of $89,175.00. Following the transaction, the director now directly owns 23,441 shares of the company’s stock, valued at approximately $278,713.49. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.90% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.